Recent Advances in Targeted Therapies for Infantile Hemangiomas

References

• Sun Y, Qiu F, Hu C, Guo Y, Lei S. Hemangioma endothelial cells and hemangioma stem cells in infantile hemangioma. Ann Plast Surg. 2022;88(2):244–249. doi:10.1097/SAP.0000000000002835
   Web of Science ®Google Scholar
• Olsen GM, Nackers A, Drolet BA. Infantile and congenital hemangiomas. Semin Pediatr Surg. 2020;29(5):150969. doi:10.1016/j.sempedsurg.2020.150969
   Web of Science ®Google Scholar
• Hasbani DJ, Hamie L. Infantile Hemangiomas. Dermatol Clin. 2022;40(4):383–392. doi:10.1016/j.det.2022.06.004
   Web of Science ®Google Scholar
• Briones M, Adams D. Neonatal vascular tumors. Clin Perinatol. 2021;48(1):181–198. doi:10.1016/j.clp.2020.11.011
   Web of Science ®Google Scholar
• Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1). doi:10.1542/peds.2018-3475
   Web of Science ®Google Scholar
• Sebaratnam DF, Rodríguez Bandera AL, Wong LF, Wargon O. Infantile hemangioma. Part 2: management. J Am Acad Dermatol. 2021;85(6):1395–1404. doi:10.1016/j.jaad.2021.08.020
   Web of Science ®Google Scholar
• Waner M. The surgical management of infantile hemangiomas. Otolaryngol Clin North Am. 2018;51(1):125–131. doi:10.1016/j.otc.2017.09.011
   Web of Science ®Google Scholar
• Castaneda S, Melendez-Lopez S, Garcia E, De la Cruz H, Sanchez-Palacio J. The role of the pharmacist in the treatment of patients with infantile hemangioma using propranolol. Adv Ther. 2016;33(10):1831–1839. doi:10.1007/s12325-016-0391-9
   PubMed Web of Science ®Google Scholar
• Ji Y, Chen S, Yang K, et al. Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2021;147(7):599–607. doi:10.1001/jamaoto.2021.0454
   Web of Science ®Google Scholar
• Pope E, Lara-Corrales I, Sibbald C, et al. Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial. JAMA Pediatr. 2022;176(1):34–41. doi:10.1001/jamapediatrics.2021.4565
   PubMed Web of Science ®Google Scholar
• Droitcourt C, Kerbrat S, Rault C, et al. Safety of oral propranolol for infantile hemangioma. Pediatrics. 2018;141(6). doi:10.1542/peds.2017-3783
   Web of Science ®Google Scholar
• Raphael MF, Breur JMPJ, Vlasveld FAE, et al. Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events – a review of the literature. Expert Opin Drug Saf. 2016;15(2):199–214. doi:10.1517/14740338.2016.1130125
   PubMed Web of Science ®Google Scholar
• Koh SP, Leadbitter P, Smithers F, Tan ST. β-blocker therapy for infantile hemangioma. Expert Rev Clin Pharmacol. 2020;13(8):899–915. doi:10.1080/17512433.2020.1788938
   PubMed Web of Science ®Google Scholar
• Ashique S, Sandhu NK, Chawla V, Chawla PA. Targeted drug delivery: trends and perspectives. Curr Drug Deliv. 2021;18(10):1435–1455. doi:10.2174/1567201818666210609161301
   PubMed Web of Science ®Google Scholar
• Alsaggar M, Liu D. Organ-based drug delivery. J Drug Target. 2018;26(5–6):385–397. doi:10.1080/1061186X.2018.1437919
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20. doi:10.1021/nn900002m
   PubMed Web of Science ®Google Scholar
• Björnmalm M, Thurecht KJ, Michael M, Scott AM, Caruso F. Bridging bio-nano science and cancer nanomedicine. ACS Nano. 2017;11(10):9594–9613. doi:10.1021/acsnano.7b04855
   PubMed Web of Science ®Google Scholar
• Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 2019;34(1). doi:10.1515/dmpt-2018-0032
   PubMedGoogle Scholar
• Aqeel R, Srivastava N, Kushwaha P. Micelles in cancer therapy: an update on preclinical and clinical status. Recent Pat Nanotechnol. 2022;16(4):283–294. doi:10.2174/1872210515666210720125717
   Web of Science ®Google Scholar
• Dartora VFC, Salata GC, Passos JS, et al. Hyaluronic acid nanoemulsions improve piplartine cytotoxicity in 2D and 3D breast cancer models and reduce tumor development after intraductal administration. Int J Biol Macromol. 2022;219:84–95. doi:10.1016/j.ijbiomac.2022.07.162
   Web of Science ®Google Scholar
• Grześkowiak BF, Maziukiewicz D, Kozłowska A, Kertmen A, Coy E, Mrówczyński R. Polyamidoamine dendrimers decorated multifunctional polydopamine nanoparticles for targeted chemo- and photothermal therapy of liver cancer model. Int J Mol Sci. 2021;22(2):738. doi:10.3390/ijms22020738
   Web of Science ®Google Scholar
• Chen Z, Zeng Y, Chen N, et al. A facile and universal method for preparing polyethylene glycol-metal hybrid nanoparticles and their application in tumor theranostics. Adv Healthc Mater. 2022;11(12):e2200044. doi:10.1002/adhm.202200044
   Web of Science ®Google Scholar
• Xu Y, Liu Y, Liu Q, et al. Co-delivery of bufalin and nintedanib via albumin sub-microspheres for synergistic cancer therapy. J Control Release. 2021;338:705–718. doi:10.1016/j.jconrel.2021.08.049
   Web of Science ®Google Scholar
• Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014;53(46):12320–12364. doi:10.1002/anie.201403036
   PubMed Web of Science ®Google Scholar
• Leung AKC, Lam JM, Leong KF, Hon KL. Infantile hemangioma: an updated review. Curr Pediatr Rev. 2021;17(1):55–69. doi:10.2174/1573396316666200508100038
   Web of Science ®Google Scholar
• Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2015;100(1):F85–91. doi:10.1136/archdischild-2014-306197
   Web of Science ®Google Scholar
• Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and management of infantile hemangioma. Pediatrics. 2015;136(4):e1060–1104. doi:10.1542/peds.2015-2485
   PubMed Web of Science ®Google Scholar
• North PE. Pediatric vascular tumors and malformations. Surg Pathol Clin. 2010;3(3):455–494. doi:10.1016/j.path.2010.07.002
   PubMedGoogle Scholar
• Wang Z, Li J, Xu X, Duan X, Cao G. Urea immunoliposome inhibits human vascular endothelial cell proliferation for hemangioma treatment. World J Surg Oncol. 2013;11(1):300. doi:10.1186/1477-7819-11-300
   Google Scholar
• Sohn CH, Park SP, Choi SH, et al. MRI molecular imaging using GLUT1 antibody-Fe3O4 nanoparticles in the hemangioma animal model for differentiating infantile hemangioma from vascular malformation. Nanomedicine. 2015;11(1):127–135. doi:10.1016/j.nano.2014.08.003
   PubMed Web of Science ®Google Scholar
• Guo X, Zhu X, Gao J, Liu D, Dong C, Jin X. PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma. Nanomedicine. 2017;12(21):2611–2624. doi:10.2217/nnm-2017-0130
   PubMed Web of Science ®Google Scholar
• Zhu X, Guo X, Liu D, Gong Y, Sun J, Dong C. Promotion of propranolol delivery to hemangiomas by using anti-vegfr antibody-conjugated poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol. 2017;13(12):1694–1705. doi:10.1166/jbn.2017.2449
   Web of Science ®Google Scholar
• Li H, Teng Y, Sun J, Liu J. Inhibition of hemangioma growth using polymer-lipid hybrid nanoparticles for delivery of rapamycin. Biomed Pharmacother. 2017;95:875–884. doi:10.1016/j.biopha.2017.08.035
   PubMed Web of Science ®Google Scholar
• Guan Y, Zuo T, Chang M, et al. Propranolol hydrochloride-loaded liposomal gel for transdermal delivery: characterization and in vivo evaluation. Int J Pharm. 2015;487(1–2):135–141. doi:10.1016/j.ijpharm.2015.04.023
   PubMed Web of Science ®Google Scholar
• Guo X, Zhu X, Liu D, Gong Y, Sun J, Dong C. Continuous delivery of propranolol from liposomes-in-microspheres significantly inhibits infantile hemangioma growth. Int J Nanomed. 2017;12:6923–6936. doi:10.2147/IJN.S137634
   PubMed Web of Science ®Google Scholar
• Zhu X, Guo X, Liu D, Gong Y, Sun J, Dong C. Significant inhibition of infantile hemangioma growth by sustained delivery of urea from liposomes-in-microspheres. Oncol Rep. 2018;39(1):109–118. doi:10.3892/or.2017.6103
   Web of Science ®Google Scholar
• Wu H, Wang X, Zheng J, et al. Propranolol-loaded mesoporous silica nanoparticles for treatment of infantile hemangiomas. Adv Healthc Mater. 2019;8(9):e1801261. doi:10.1002/adhm.201801261
   Web of Science ®Google Scholar
• Wu H, Wang X, Liang H, Zheng J, Huang S, Zhang D. Enhanced efficacy of propranolol therapy for infantile hemangiomas based on a mesoporous silica nanoplatform through mediating autophagy dysfunction. Acta Biomater. 2020;107:272–285. doi:10.1016/j.actbio.2020.02.033
   Web of Science ®Google Scholar
• Guo X, Yuan Z, Xu Y, Wei M, Fang Z, Yuan WE. A fluorinated low-molecular-weight PEI/HIF-1α shRNA polyplex system for hemangioma therapy. Biomater Sci. 2020;8(8):2129–2142. doi:10.1039/D0BM00171F
   PubMed Web of Science ®Google Scholar
• Zeng L, Tao C, Liu Z, et al. Preparation and evaluation of cubic nanoparticles for improved transdermal delivery of propranolol hydrochloride. AAPS Pharm Sci Tech. 2020;21(7):266. doi:10.1208/s12249-020-01809-7
   PubMed Web of Science ®Google Scholar
• Khalil RM, El Arini SK, AbouSamra MM, Zaki HS, El-Gazaerly ON, Elbary AA. Development of lecithin/chitosan nanoparticles for promoting topical delivery of propranolol hydrochloride: design, optimization and in-vivo evaluation. J Pharm Sci. 2021;110(3):1337–1348. doi:10.1016/j.xphs.2020.11.025
   PubMed Web of Science ®Google Scholar
• Liao S, Wu J, Li Z, et al. Study on the mechanism of targeted poly(lactic-coglycolic acid) nano-delivery carriers in the treatment of hemangiomas. J Nanosci Nanotechnol. 2021;21(2):1236–1243. doi:10.1166/jnn.2021.18689
   Google Scholar
• Li X, Ren X, Liang J, Ma W, Wang Z, Yang Z. Delivery of sodium morrhuate to hemangioma endothelial cells using immunoliposomes conjugated with anti-VEGFR2/KDR antibody. Int J Nanomed. 2017;12:6963–6972. doi:10.2147/IJN.S144056
   PubMed Web of Science ®Google Scholar
• Li H, Teng Y, Xu X, Liu J. Enhanced rapamycin delivery to hemangiomas by lipid polymer nanoparticles coupled with anti-VEGFR antibody. Int J Mol Med. 2018;41(6):3586–3596. doi:10.3892/ijmm.2018.3518
   Web of Science ®Google Scholar
• Li H, Wang X, Guo X, Wan Q, Teng Y, Liu J. Development of rapamycin-encapsulated exosome-mimetic nanoparticles-in-PLGA microspheres for treatment of hemangiomas. Biomed Pharmacother. 2022;148:112737. doi:10.1016/j.biopha.2022.112737
   Web of Science ®Google Scholar
• Zhao ZL, Liu C, Wang QZ, Wu HW, Zheng JW. Engineered exosomes for targeted delivery of miR-187-3p suppress the viability of hemangioma stem cells by targeting Notch signaling. Ann Transl Med. 2022;10(11):621. doi:10.21037/atm-21-4138
   Web of Science ®Google Scholar
• Li Y, Lin TY, Luo Y, et al. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun. 2014;5(1):4712. doi:10.1038/ncomms5712
   PubMedGoogle Scholar
• Orbay H, Li Y, Xiao W, Cherry SR, Lam K, Sahar DE. Developing a nanoparticle-delivered high-efficacy treatment for infantile hemangiomas using a mouse hemangioendothelioma model. Plast Reconstr Surg. 2016;138(2):410–417. doi:10.1097/PRS.0000000000002403
   PubMed Web of Science ®Google Scholar
• Wu W, Wang H, Hao J, Gao Z, Li F, Chen Y. Therapeutic efficacy of propranolol for infantile hemangiomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128(2):132–138. doi:10.1016/j.oooo.2019.04.014
   Web of Science ®Google Scholar
• Tang YJ, Zhang ZZ, Chen SQ, et al. Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas. J Huazhong Univ Sci Technolog Med Sci. 2015;35(5):759–762. doi:10.1007/s11596-015-1503-5
   Google Scholar
• Baveloni FG, Riccio BVF, Di Filippo LD, Fernandes MA, Meneguin AB, Chorilli M. Nanotechnology-based drug delivery systems as potential for skin application: a review. Curr Med Chem. 2021;28(16):3216–3248. doi:10.2174/0929867327666200831125656
   PubMed Web of Science ®Google Scholar
• Sharma G, Thakur K, Raza K, Singh B, Katare OP. Nanostructured lipid carriers: a new paradigm in topical delivery for dermal and transdermal applications. Crit Rev Ther Drug Carrier Syst. 2017;34(4):355–386. doi:10.1615/CritRevTherDrugCarrierSyst.2017019047
   PubMed Web of Science ®Google Scholar
• Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5–24. doi:10.1016/S0169-409X(97)00048-3
   PubMed Web of Science ®Google Scholar
• Swider E, Koshkina O, Tel J, Cruz LJ, de Vries IJM, Srinivas M. Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. Acta Biomater. 2018;73:38–51. doi:10.1016/j.actbio.2018.04.006
   PubMed Web of Science ®Google Scholar
• Su H, Wang Y, Gu Y, Bowman L, Zhao J, Ding M. Potential applications and human biosafety of nanomaterials used in nanomedicine. J Appl Toxicol. 2018;38(1):3–24. doi:10.1002/jat.3476
   PubMed Web of Science ®Google Scholar
• Brouwer A, Knook DL. The reticuloendothelial system and aging: a review. Mech Ageing Dev. 1983;21(3–4):205–228. doi:10.1016/0047-6374(83)90042-8
   Web of Science ®Google Scholar
• Zhang Y, Liu Q, Zhang X, et al. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. J Nanobiotechnology. 2022;20(1):279. doi:10.1186/s12951-022-01472-z
   Web of Science ®Google Scholar
• Hager S, Fittler FJ, Wagner E, Bros M. Nucleic acid-based approaches for tumor therapy. Cells. 2020;9(9):2061. doi:10.3390/cells9092061
   PubMed Web of Science ®Google Scholar
• Zhang J, Tang H, Liu Z, Chen B. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy. Int J Nanomed. 2017;12:8483–8493. doi:10.2147/IJN.S148359
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine. 2012;7(10):1577–1590. doi:10.2217/nnm.12.128
   PubMed Web of Science ®Google Scholar
• Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921–7924. doi:10.7150/thno.49577
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. doi:10.1186/s12951-018-0392-8
   PubMed Web of Science ®Google Scholar
• Liu J, Luo Z, Zhang J, et al. Hollow mesoporous silica nanoparticles facilitated drug delivery via cascade pH stimuli in tumor microenvironment for tumor therapy. Biomaterials. 2016;83:51–65. doi:10.1016/j.biomaterials.2016.01.008
   PubMed Web of Science ®Google Scholar
• Watermann A, Brieger J. Mesoporous silica nanoparticles as drug delivery vehicles in cancer. Nanomaterials. 2017;7(7):189. doi:10.3390/nano7070189
   Web of Science ®Google Scholar
• Rajagopal P, Duraiswamy S, Sethuraman S, Giridhara Rao J, Krishnan UM. Polymer-coated viral vectors: hybrid nanosystems for gene therapy. J Gene Med. 2018;20(4):e3011. doi:10.1002/jgm.3011
   Web of Science ®Google Scholar
• Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. Aaps j. 2021;23(4):78. doi:10.1208/s12248-021-00608-7
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555. doi:10.1038/nrg3763
   PubMed Web of Science ®Google Scholar
• Jiang HL, Islam MA, Xing L, et al. Degradable polyethylenimine-based gene carriers for cancer therapy. Top Curr Chem. 2017;375(2):34. doi:10.1007/s41061-017-0124-9
   Web of Science ®Google Scholar
• de Jong S, Itinteang T, Withers AH, Davis PF, Tan ST. Does hypoxia play a role in infantile hemangioma? Arch Dermatol Res. 2016;308(4):219–227. doi:10.1007/s00403-016-1635-x
   PubMed Web of Science ®Google Scholar
• Sharp FR, Lu A, Tang Y, Millhorn DE. Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab. 2000;20(7):1011–1032. doi:10.1097/00004647-200007000-00001
   PubMed Web of Science ®Google Scholar
• Zhang W, Sun L, Gao H, Wang S. Mechanism of the HIF-1α/VEGF/VEGFR-2 pathway in the proliferation and apoptosis of human haemangioma endothelial cells. Int J Exp Pathol. 2023;104(5):258–268. doi:10.1111/iep.12485
   Web of Science ®Google Scholar
• Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, Gosain AK. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann Surg. 2012;256(1):146–156. doi:10.1097/SLA.0b013e318254ce7a
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2010;31(2):358–365. doi:10.1016/j.biomaterials.2009.09.048
   PubMed Web of Science ®Google Scholar
• Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571. doi:10.1016/j.ijpharm.2021.120571
   PubMed Web of Science ®Google Scholar
• Carita AC, Eloy JO, Chorilli M, Lee RJ, Leonardi GR. Recent advances and perspectives in liposomes for cutaneous drug delivery. Curr Med Chem. 2018;25(5):606–635. doi:10.2174/0929867324666171009120154
   PubMedGoogle Scholar
• Ferreira Soares DC, Domingues SC, Viana DB, Tebaldi ML. Polymer-hybrid nanoparticles: current advances in biomedical applications. Biomed Pharmacother. 2020;131:110695. doi:10.1016/j.biopha.2020.110695
   PubMed Web of Science ®Google Scholar
• Narmani A, Jahedi R, Bakhshian-Dehkordi E, et al. Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy. Expert Opin Drug Deliv. 2023;20(7):937–954. doi:10.1080/17425247.2023.2223941
   PubMed Web of Science ®Google Scholar
• Dave V, Tak K, Sohgaura A, Gupta A, Sadhu V, Reddy KR. Lipid-polymer hybrid nanoparticles: synthesis strategies and biomedical applications. J Microbiol Methods. 2019;160:130–142. doi:10.1016/j.mimet.2019.03.017
   PubMed Web of Science ®Google Scholar
• Go YK, Leal C. Polymer-lipid hybrid materials. Chem Rev. 2021;121(22):13996–14030. doi:10.1021/acs.chemrev.1c00755
   Web of Science ®Google Scholar
• Tan KX, Danquah MK, Sidhu A, Yon LS, Ongkudon CM. Aptamer-mediated polymeric vehicles for enhanced cell-targeted drug delivery. Curr Drug Targets. 2018;19(3):248–258. doi:10.2174/1389450117666160617120926
   Web of Science ®Google Scholar
• Novio F. Design of targeted nanostructured coordination polymers (NCPs) for cancer therapy. Molecules. 2020;25(15):3449. doi:10.3390/molecules25153449
   Web of Science ®Google Scholar
• Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol. 2008;214(1):3–9. doi:10.1002/path.2283
   PubMed Web of Science ®Google Scholar
• Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest. 2008;118(7):2592–2599. doi:10.1172/JCI33493
   PubMed Web of Science ®Google Scholar
• Oszajca K, Szemraj J, Wyrzykowski D, Chrzanowska B, Salamon A, Przewratil P. Single-nucleotide polymorphisms of VEGF-A and VEGFR-2 genes and risk of infantile hemangioma. Int J Dermatol. 2018;57(10):1201–1207. doi:10.1111/ijd.14127
   Web of Science ®Google Scholar
• Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer. 2006;42(18):3127–3139. doi:10.1016/j.ejca.2006.09.015
   PubMed Web of Science ®Google Scholar
• Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med. 2011;32(2):88–111. doi:10.1016/j.mam.2011.04.004
   PubMed Web of Science ®Google Scholar
• Tu JB, Dong Q, Hu XY, et al. Proteomic analysis of mitochondria from infantile hemangioma endothelial cells treated with sodium morrhuate and its liposomal formulation. J Biochem Mol Toxicol. 2012;26(9):374–380. doi:10.1002/jbt.21436
   Web of Science ®Google Scholar
• Fukuta T, Kogure K. Biomimetic nanoparticle drug delivery systems to overcome biological barriers for therapeutic applications. Chem Pharm Bull. 2022;70(5):334–340. doi:10.1248/cpb.c21-00961
   Web of Science ®Google Scholar
• Wang R, Sha X. Biomimetic drug delivery systems oriented by biological function in tumor targeting. Curr Drug Targets. 2021;22(8):882–895. doi:10.2174/1389450122666210114095859
   Web of Science ®Google Scholar
• Liang T, Zhang R, Liu X, et al. Recent advances in macrophage-mediated drug delivery systems. Int J Nanomed. 2021;16:2703–2714. doi:10.2147/IJN.S298159
   PubMed Web of Science ®Google Scholar
• Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37. doi:10.1038/nrc.2016.108
   PubMed Web of Science ®Google Scholar
• Kadkhoda J, Tarighatnia A, Barar J, Aghanejad A, Davaran S. Recent advances and trends in nanoparticles based photothermal and photodynamic therapy. Photodiagnosis Photodyn Ther. 2022;37:102697. doi:10.1016/j.pdpdt.2021.102697
   PubMed Web of Science ®Google Scholar
• Li Z, Cao Z, Li N, et al. M2 macrophage-derived exosomal lncrna lncRNA MIR4435-2HG progression of infantile hemangiomas by targeting HNRNPA1. Int J Nanomed. 2023;18:5943–5960. doi:10.2147/IJN.S435132
   PubMed Web of Science ®Google Scholar
• Wu Y, Li H, Xie J, Wang F, Cao D, Lou Y. MiR‑139‑5p affects cell proliferation, migration and adipogenesis by targeting insulin‑like growth factor 1 receptor in hemangioma stem cells. Int J Mol Med. 2020;45(2):569–577. doi:10.3892/ijmm.2019.4430
   Web of Science ®Google Scholar